The biological drug API manufacturing market is estimated to grow at a CAGR of 9.5% in the first half of the forecast period. In 2018, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry.
How this 211-page report delivers:
• Biological Drug API Manufacturing Services market forecast to 2029
• Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems:
• Mammalian cell culture
• Microbial fermentation
• Other expression platforms
• Biological Drug API Manufacturing Services market forecast to 2029 by Therapeutic Area:
• Monoclonal antibody (mAb) therapies
• Vaccines
• Insulin therapies
• Interferon therapies
• Growth hormones
• Other Therapeutic Areas
• Biological Drug API Manufacturing Services market forecast to 2029 by Regional and National Market:
• North America: US, Canada
• Europe: Germany, France, the UK, Switzerland, Spain, Italy, Rest of Europe
• BRIC: Brazil, Russia, China, India
• Japan
• South Korea
• Singapore
• RoW
• Profiles leading companies that offer biotech API manufacturing services to the pharmaceutical industry. Leading CMOs profiled in this report are:
• Abbvie
• Boehringer Ingelheim BioXcellence
• Catalent
• Celltrion
• Cytovance Biologics
• Fujifilm Diosynth Biotechnologies
• GSK
• Lonza
• Patheon N.V.
• Rentschler Biopharma
• Samsung BioLogics
• Sandoz
• Teva
• Provides qualitative analysis: SWOT and STEP Analysis of the biological drug API manufacturing market.
• Key questions answered by this report:
• How is the biological drug API manufacturing services market evolving?
• What is driving and restraining the biological drug API manufacturing services market?
• What are the market shares of each main segment of the overall biological drug API manufacturing services market in 2018?
• How will each main biological drug API manufacturing services submarket grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for biological drug API manufacturing services submarkets develop from 2019 to 2029?
• What will be the main drivers for the overall market from 2019 to 2029?
• How will political and regulatory forces influence the regional markets and submarkets?
• Will leading national biological drug API manufacturing services markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2029 and which countries will lead the market in 2029?
• Who are the leading companies and what are their prospects?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry evolve during the period 2019 to 2029, and which trends will be important?
Visiongain’s study is intended for anyone requiring commercial analyses for the biological drug API manufacturing market. You find data, trends and predictions.
Buy our report today Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029: Mammalian Cell Cultures, Microbial Fermentations, and Other Expression Systems; Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines, and Others Therapeutic Areas.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Contract Biological Drug API Manufacturing: World Market Review 2018
1.2 Benefits of this Report
1.2.1 How This Report Delivers
1.2.2 Main Questions Answered by This Analytical Report
1.3 Who is This Report For?
1.4 Methods of the Study
1.5 Frequently Asked Questions (FAQ)
1.6 Associated Reports
1.7 About Visiongain
2. Introduction to Biological Drug API Manufacturing Services
2.1 What are Biological Drug API Manufacturing Services?
2.1.1 Producing Biological drug API: An Overview of the Manufacturing Process
2.1.2 Defining the Biological Drug API Manufacturing Market
2.1.3 Differing Expression Systems to Manufacture APIs
2.2 Challenges in Manufacturing Biological drug API
2.3 Outsourcing: A Common Trend in Biological Drug API Manufacturing Services
2.4 Future Trends for the Biological Drug API Manufacturing Services Market
3. Biological Drug API Manufacturing Services: World Market Outlook and Forecast 2019-2029
3.1 The Contract Biological Drug API Manufacturing Services Market Performance, 2018
3.1.1 Contract Biological Drug API Manufacturing Services: Forecast 2018-2029
3.2 Drivers and Restraints in the Biological Drug API Manufacturing Services Market
3.2.1 Drivers in the Biological Drug API Manufacturing Market
3.2.1.1 The Ageing Population is a Driver for Growth
3.2.1.2 The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
3.2.1.3 Outsourcing as a Driver for Growth
3.2.1.4 Opportunities from the Long Pipeline Will Drive Growth
3.2.1.5 Increased Investment in Orphan Drugs from Companies
3.2.1.6 Emerging Markets Will Grow and Influence the Market
3.2.1.7 Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
3.2.2 Restraints on Growth in the Biological Drug API Manufacturing Services Market
3.2.2.1 Pricing Pressures Will Limit Market Growth
3.2.2.2 Regulatory Restrictions Will Increase
3.2.2.3 Overcapacity Will Be Adverse to Market Growth for CMOs
3.2.2.4 Complexity of API Production is a Challenge
3.3 Outlook for the Outsourced Biological drug API Services: Increased Demand
4. Biological Drug API Manufacturing Services Submarket by Expression Systems: World Market Outlook and Forecasts 2019-2029
4.1 Submarkets for the Biological Drug API Manufacturing Services Industry
4.1.1 The Mammalian Cell Culture Submarket
4.1.1.1 The Mammalian Cell Culture Submarket Forecast 2018-2029
4.1.1.2 ADCs and Next-Generation Antibodies Will Drive Growth 2018-2029
4.1.2 The Microbial Fermentation Submarket
4.1.2.1 The Microbial Fermentation Submarket Forecast 2018-2029
4.1.2.2 Increase in Demand for Insulin Will Drive Growth 2018-2029
4.1.3 Other APIs Expression Systems Are Still in Development
4.1.3.1 Plant-Made Pharmaceuticals
4.1.3.2 Yeast Cell Expression Systems
4.1.3.3 Insect Cell Expression Systems
4.1.3.4 Other Expression Systems Submarket Forecast 2018-2029
4.2 Chapter Summary: Positive Growth for the Market
5. Biological Drug API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors: 2019-2029
5.1 Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
5.1.1 Contract API Monoclonal Antibody Manufacturing Forecast 2018-2029
5.1.2 Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
5.2 Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
5.2.1 Contract API Vaccine Market: Outlook and Forecast 2018-2029
5.2.2 Challenges in Manufacturing Vaccines
5.3 Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
5.3.1 Contract API Insulin Analogues Forecast 2018-2029
5.3.2 Insulin Analogues: In-House Production Restrains Contract API Insulin Therapies Market Growth
5.3.3 Development Trends in the Contract API Insulin Market 2018 to 2029
5.4 Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
5.4.1 Contract API Interferon Market Forecast 2018-2029
5.4.2 Unlikely to be Opportunities in the Contract API Interferon Market
5.5 Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
5.5.1 Contract API Growth Hormone Market Forecast 2018 to 2029
5.5.2 Most Manufacturing is In-House for Growth Hormone Production
5.5.3 Long-Acting Therapies Provide Opportunity for Outsourcing
5.6 Chapter Summary: Outsourcing for Key Biological
Products 2018-2029
6. Leading National Markets for Contract Biological Drug API Manufacturing Services Market Forecast to 2029
6.1 Regional Breakdown of the World Biological Drug API Manufacturing Services Market
6.1.1 North America and EU Dominate Growth for Leading National Submarkets 2018-2029
6.1.2 National Revenue Shares by 2029: Emerging Market Growth
6.2 Contract Biological Drug API Manufacturing in EU Market 2018-2029
6.2.1 Strong Growth for the EU Revenue Forecasts 2018-2029
6.2.2 Forecasts for Switzerland and Leading EU National Revenues 2018-2029
6.2.2.1 Germany Leads the EU Biotech Market with Strong Growth
6.2.2.2 UK: Strong Research Sector Will Drive Market Growth
6.2.2.3 France: Strong Vaccine Development Industry
6.2.2.4 Switzerland: Headquarters for Leading Companies
6.2.2.5 Spain: Numerous Biotech Companies
6.2.2.6 Italy: Outlook and Forecast 2018-2029
6.3 Contract Biological Drug API Manufacturing in North America Market 2018-2029
6.3.1 Forecasts for North America Leading National Revenues 2018-2029
6.3.2 US: A Market Leader in Biological Drug API Manufacturing
6.3.3 Canada: A Market Leader in Biological Drug API Manufacturing
6.3.4 Mexico: A Market Leader in Biological Drug API Manufacturing
6.4 BRIC Market: Contract Biological Drug API Manufacturing Services Market 2018-2029
6.4.1 Emerging Nations May Develop a Presence in the Biologics Market
6.4.2 Increased Demand for Biosimilars and Biological Drugs 2018-2029
6.4.3 China is Poised for Growth: Forecast for 2018-2029
6.4.4 India Offers a Lower-Cost Advantage for Biological Drug API Manufacturing Services: Forecast 2018-2029
6.4.5 Brazilian and Russian Governments Promoting Domestic Biotech Development
6.4.5.1 Russian Biological Drug API Manufacturing Services Forecast: 2018-2029
6.4.5.2 Brazilian Biological Drug API Manufacturing Services Forecast: 2018-2029
6.5 Forecasts for the Other Leading Nationals Revenues 2018-2029
6.5.1 Japan: A Less Mature Contract Manufacturing Market
6.5.2 Leading CMOs Celltrion and Samsung BioLogics Drive the Market in South Korea: Market Forecast, 2018-2029
6.5.3 Singapore: Market Forecast, 2018-2029
6.6 Summary of Chapter: Outlook for Leading National Submarkets 2018-2029
7. Leading CMOs in the Biological Drug API Manufacturing Services Market
7.1 Four Companies Led the Market in 2018
7.2 Leading Companies by Capacity
7.2.1 Small-Scale Biopharmaceutical Manufacturing is a Common Trend
7.2.2 Barriers to Market Entry 2018-2029
7.2.2.1 The High Cost of Facilities: Acquisition as a Cheaper Alternative
7.3 FDA Opens Barriers for the Biosimilars Market
7.4 Boehringer Ingelheim BioXcellence
7.4.1 Strategic Outlook: Expanding into the Asian Market
7.5 Celltrion: Biologics Leader in Asia
7.5.1 Celltrion: Following Partnerships and Joint Ventures Path
7.6 Patheon N.V.: Target for Mergers and Acquisitions
7.7 Lonza Has the Largest Worldwide Cell Culture Capacity
7.7.1 Lonza: Biopharmaceutical Core Competency as a Strategy for Growth
7.8 Other Market Players of Interest in 2018
7.9 Samsung BioLogics: Focusing on Biosimilars
7.9.1 Samsung BioLogics: Partnership Strategy for Future Expansion
7.10 Cytovance Biologics: Plans to Expand
7.11 Fujifilm Diosynth Biotechnologies
7.11.1 Facility and Service Expansion for the Future
7.12 Leading Biopharma Companies Operate CMO Divisions
7.13 AbbVie Contract Manufacturing: Strength through Acquisition
7.14 GSK Biopharmaceuticals
7.15 Sandoz: Expertise in Biologics and Biosimilars
7.16 Rentschler Biopharma: Recent Expansions
7.17 Teva: A Future Player in the Biologics Market
7.18 Catalent: Follows Acquisition and Investment Strategy for Expansion
8. Biological Drug API Manufacturing Services Market Industry Trends: Qualitative Analysis
8.1 SWOT Analysis: Strengths and Weaknesses of the Biological Drug API Manufacturing Services Market 2018
8.1.1 Strength: Biopharmaceutical Demand for Outsourcing is increasing
8.1.2 Weakness: A Fragmented Market with a Costly and Difficult Manufacturing Process
8.1.3 Opportunities for the Biological Drug API Manufacturing Services Market 2018-2029
8.1.4 Threats for the Biological Drug API Manufacturing Services Market 2018-2029
8.2 STEP Analysis of the Biological Drug API Manufacturing Services Market
8.2.1 Social Factors: Drug Pricing Pressures to Meet Demand for an Increasing Ageing Population
8.2.2 Technological Factors: Advances Will Drive Growth
8.2.2.1 Single-Use Technology: A Vital Trend for the Future
8.2.3 Economic Factors: The High Cost of Manufacturing Will Lead to Outsourcing
8.2.4 Political Factors: Regulatory Requirements Need to Be Met
8.3 Trends in Biological Drug Development 2018-2029
8.3.1 Biosimilars Will Be an Important Opportunity for CMOs
8.3.2 CMOs are investing in Next-Generation Antibody Development
8.3.3 Orphan Drugs and Personalised Medicine: Trend for Smaller Batches
8.3.4 Outlook for Single-Use Technologies in Biological Drug API Manufacturing 2018-2029
8.3.4.1 Future Direction: Single-Use Systems will be Essential
8.3.5 Outsourcing Trends for Biological Drug API Manufacturing 2018-2029
8.3.5.1 Biopharma Companies Continue to Invest in In-House Facilities
8.3.5.2 Off-shoring Biological Drug API Manufacturing to Emerging Markets: Not a Trend for this Decade?
8.3.5.3 Overcapacity is a Risk for the Biotech CMO Industry
8.3.5.4 Future Trends: Strategic Partnering
8.3.5.5 Alternative Expression Methods
8.4 Regulations and Effects on the Biological Drug API Manufacturing Services Industry
8.4.1 Effect on the Emerging Biological Drug API Manufacturing Services Market 2018-2029
8.4.2 Regulations in Other Countries in the Biological drug API Market
8.5 Chapter Summary: Industry Trends for Contract Biological Drug API Manufacturing to 2028
9. Conclusions
9.1 The Contract Biological Drug API Manufacturing Services Market
9.2 Outlook for the Biological Drug API Manufacturing Services Market
9.2.1 Mammalian Cell Culture is the Leading Expression Platform for Outsourced Biological Drug API Manufacturing
9.2.2 The US and EU Markets Lead for the Global Biological Drug API Manufacturing Services Market in 2017
9.2.3 Single-Use Technology Will Become Indispensable for Success in the Market
9.3 Growth in the Market 2018-2029
9.3.1 The Future of the Biological Drug API Manufacturing Services Marketplace
Appendices
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2018
Table 3.1 Contract Biological Drug API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.1 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts by Expression Systems Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.2 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Mammalian Cell Culture Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.3 ADC Pipeline 2019
Table 4.4 Recent ADC’s Investment
Table 4.5 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Microbial Fermentation Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.6 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Other APIs Expression Systems Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 5.1 Top Ten Best-Selling Drugs in 2018: Revenue ($bn)
Table 5.2 Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Therapeutic Area, 2018-2029
Table 5.3 Monoclonal Antibody Types and Sources
Table 5.4 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Monoclonal Antibodies Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 5.5 The Four Classes of Next- Generation Antibody Therapies
Table 5.6 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Vaccines Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 5.7 Comparison between biomanufacturing platforms for Vaccine Production: VLP
Table 5.8 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Insulin Analogues Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 5.9 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Interferon Therapies Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 5.10 Contract Biological Drug API Manufacturing Services Market Revenue Forecasts for Growth Hormones Submarket ($bn), AGR (%), CAGR (%), 2018-2029
Table 5.11 Selected Long-Acting Growth Hormones in Development, 2018
Table 6.1 Contract Biological Drug API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2018
Table 6.2 Contract Biological Drug API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Submarket, 2018
Table 6.3 Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Region, 2018-2029
Table 6.4 Contract Biological Drug API Manufacturing Market: Leading Nationals Revenue Shares (%), 2018, 2024 & 2029
Table 6.5 EU and Switzerland Contract Biological Drug API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2018-2029
Table 6.6 EU and Switzerland Contract Biological Drug API Manufacturing: Revenues ($bn) and Shares (%) by Leading Country, 2018
Table 6.7 Germany Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2018-2029
Table 6.8 UK Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2018-2029
Table 6.9 France Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2018-2029
Table 6.10 Switzerland Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.11 Spain Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2018-2029
Table 6.12 Italian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.13 North America Contract Biological Drug API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2018-2029
Table 6.14 US Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.15 Canada Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.16 Mexico Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.17 Contract Biological Drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.18 BRIC Markets: API Revenues ($bn) and Market Shares (%), 2018
Table 6.19 Contract Biological Drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.20 Chinese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.21 India Contract Biological Drug API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%) 2018-2029
Table 6.22 Russia Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.23 Brazilian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.24 Contract Biological Drug API Manufacturing Market: Other Leading Nationals Revenue Forecasts ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.25 Japanese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.26 South Korean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 6.27 Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Singapore, 2019
Table 6.28 Singaporean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Table 7.1 Leading Biological drug API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2018
Table 7.2 Selected Other Biological drug API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2018
Table 7.3 Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2018
Table 7.4 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2016-2018
Table 7.5 Celltrion Revenue ($bn), 2016-2018
Table 7.6 Lonza Pharma & Biotech Revenue ($bn), 2016-2018
Table 7.7 Samsung BioLogics CMO Revenue ($bn), 2016-2018
Table 7.8 Sandoz Biosimilar Pipelines: Selected Biosimilars, 2019
Table 8.1 Contract Biological Drug API Manufacturing Market: Strengths and Weaknesses, 2018
Table 8.2 Contract Biological Drug API Manufacturing Market: Opportunities and Threats, 2018-2029
Table 8.3 Biological Drug API Manufacturing Services Market: STEP Analysis, 2018
Table 8.4 Selected EU-Approved Biosimilars: Manufacturers and Companies, 2018
Table 8.5 Key Approved Next-Generation Antibody Therapies, 2018
Table 9.1 Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Expressions Submarket, 2019, 2021, 2023, 2025, 2027 and 2029
Table 9.2 Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2019, 2021, 2023, 2025, 2027 and 2029
List of Figures
Figure 1.1 Biological Drug API Manufacturing Services Submarkets 2018
Figure 2.1 Steps for Biological Drug Manufacturing, 2018
Figure 2.2 Contract API Manufacturing: Market Shares by Sector (%), 2018
Figure 2.3 Future Trends in the Biological Drug API Manufacturing Market, 2018-2029
Figure 3.1 Contract Biological Drug API Manufacturing Services Market: Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 3.2 Contract Biological Drug API Manufacturing: Market Drivers
Figure 3.3 Contract Biological Drug API Manufacturing: Market Restraints
Figure 4.1 Contract Biological Drug API Manufacturing: Market Shares (%) by Expression Systems Submarket, 2018
Figure 4.2 Mammalian Cell Culture Submarket Forecast: Revenue ($bn), AGR (%), 2019-2029
Figure 4.3 Mammalian Cell Culture Submarket: Drivers and Restraints
Figure 4.4 Microbial Fermentation Submarket Forecast ($bn), AGR (%), 2019-2029
Figure 4.5 Microbial Fermentation Submarket: Drivers and Restraints, 2019
Figure 4.6 Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2018-2029
Figure 5.1 Contract Biological Drug API Manufacturing: Market Shares (%) by Therapeutic Area Submarket, 2018
Figure 5.2 Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 5.3 Vaccines Submarket Forecast, Revenue ($bn), AGR (%), 2018-2029
Figure 5.4 Insulin Analogues Submarket Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 5.5 Interferon Therapies Submarket Forecast, Revenue ($bn), AGR (%), 2018-2029
Figure 5.6 Growth Hormones Submarket Forecast, Revenue ($bn), AGR (%), 2018-2029
Figure 6.1 Contract Biological Drug API Manufacturing: Market Shares (%) by Region, 2018
Figure 6.2 Contract Biological Drug API Manufacturing: Market Shares by Leading Nationals (%), 2018
Figure 6.3 Contract Biological Drug API Manufacturing: Market Shares by Leading Nationals (%), 2024
Figure 6.4 Contract Biological Drug API Manufacturing: Market Shares by Leading Nationals (%), 2029
Figure 6.5 EU and Switzerland Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.6 EU Contract Biological Drug API Manufacturing: Leading National Revenue Shares (%), 2018
Figure 6.7 Germany Contract Biological Drug API Manufacturing Revenue Forecast ($bn), 2018-2029
Figure 6.8 UK Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.9 France Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.10 Switzerland Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.11 Spanish Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.12 Italian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.13 North America Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.14 US Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.15 Canada Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.16 Mexico Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.17 Contract Biological Drug API Manufacturing Market: BRIC National Revenue Forecasts ($bn), AGR (%), 2018-2029
Figure 6.18 Biologics Market: BRIC Revenue Shares (%), 2018
Figure 6.19 Chinese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2018-2029
Figure 6.20 India Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.21 Russia Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.22 Brazilian Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.23 Japanese Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.24 South Korean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 6.25 Singaporean Contract Biological Drug API Manufacturing Revenue Forecast ($bn), AGR (%), 2018-2029
Figure 7.1 Leading Biological drug API CMOs: Mammalian Cell Culture Manufacturing Scale, 2018
Figure 7.2 Leading Biological drug API CMOs: Microbial Fermentation Manufacturing Scale, 2018
Figure 7.3 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2016-2018
Figure 7.4 Celltrion Revenue ($bn), 2016-2018
Figure 7.5 Patheon N.V.: Revenue ($bn), 2014-2016
Figure 7.6 Lonza Pharma & Biotech Revenue ($bn), 2016-2018
Figure 7.7 Samsung BioLogics CMO Revenue ($bn), 2016-2018
Figure 9.1 Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Expressions Submarket, 2018-2029
Figure 9.2 Contract Biological Drug API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2019, 2021, 2023, 2025, 2027 and 2029
Abasria
AbbVie
Accord Healthcare
Acquired Cedarburg Pharmaceuticals
Actavis Generics
Adaptimmune Therapeutics
Agensys
Althera Technologies
Altus Pharmaceuticals
Amgen
Apotex
Aptuit
arGEN-X
Ascendis Pharma A/S
Asterion
Astra Zeneca
Avid Bioservices Inc
Bakhu Pharma.
Banner Life Sciences
Basaglar
Baxalta
Baxter
Bayer
Bever Pharmaceutical
Biocad
Biocon
Biogen
Biogen Idec
BMS
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence
Bolder BioTechnology
Calico Life Science
Caspugel
Catalent Biologics
Celgene
Celldex Therapautics
Celltrion
Cinfa
CMC Biologics
CMIC Holdings Co. Ltd.
CMO Relthy Laboratórios
Cook Pharmica
Critical Pharmaceuticals
CT Arzneimittel
Cytos Biotechnology
Cytovance Biologics
DPx Fine Chemicals
DPx Holdings B.V.
DSM Biologics
DSM Sinochem Pharmaceuticals
Eli Lily
EMD Millipore
FDA
Ferring Pharmaceuticals
Filnox Biotech
Fresenius
Fujifilm Diosynth Biotechnologies
Gallus BioPharmaceuticals,
GE Healthcare
Genentech
GeneScience Pharmaceuticals Co., Ltd.
Genexine and Handok
Genmab
Genzyme
Germany’s Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Gilead Sciences, Inc.
GSK
Hanmi Pharmaceutical Co.
Hexal
Index Ventures
Infarco
Infinity Pharmaceuticals
Inno Biologics
Innovation Network Corporation of Japan (INCJ),
Japanese Ministry of Health, Labour and Welfare
Johnson and Johnson
Johnson Matthey
JSR Corporation
Kalon Biotherapeutics
KBI Biopharma, Inc.
Kemwell
Kyowa Hakko Kirin
Labrys Biologics Inc,
Laureate Biopharma
LG Life Sciences, Ltd.
Lonza
Matrix Laboratories
Merck
Mitsubishi Gas Chemical Company
Mylan
Neopharm
NHS
NICE
Nikon
Nippon kayaku
Norbitec
Novartis
Novasep
Novo Nordisk
Nuron Biotech
Nycomed
Opko Health
Patheon
PelChem
Peregrine Pharmaceuticals
Perrigo
Pfizer
Pharmstandard
Phyton Biotech
Piramal Healthcare
Precision Biologics
Progenics
Quintiles
Rebtschler Biotechnologie
Recepta Biopharma
Redwood Bioscience
Rentschler
Rentschler Biotechnologie
Roche
RoYal DSM
SAFC
Samsung BioLogics
Sanofi
SCM Pharma
Seattle Genetics
ShangPharma
SICOR Biotech
Sigma-Aldrich Corporation
Stada
SunShine Biopharma
SynCo BioPartners
Takeda
Teva
Therapure Biopharma
Thermo Fisher
Toyobo Biologics
Transgene SA
Versartis
Vertex
Vida Pharma
VTU
WHO
WuXi Biologics,
WuXi PharmaTech
Zhangjiang Biotech
Zhejiang Jiang Yuan Tang Biotechnology
ZJ Base
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
